Predictive factors for early super response to bimekizumab in 341 patients with psoriasis-a 24-week short-term multicenter real-life experience

Abstract

Purpose/Aim of the study: The efficacy of bimekizumab was shown in moderate to severe plaquepsoriasis. The aim of this study was to investigate the early super responder (ESR) profile (at week 4)to bimekizumab.Materials and Methods: We performed a multicenter retrospective study in 20 Dermatology outpatientclinics in Turkey. Adult patients with moderate-to-severe psoriasis who were under bimekizumab for atleast 12 weeks were enrolled.Results: A total of 341 adult patients were included. 136 had nail psoriasis (39.9%), 148 had psoriaticarthritis (PsA) (43.4%), 223 (65.4%) had at least one difficult-to-treat area involvement, 155 (45.5%) werebio-naïve, 110 (32.5%) had ≥ 2 biologics history. At week 4, PASI75 was achieved in 144 patients(49.8%), PASI90 was achieved in 88 patients (30.4%), PASI100 was achieved in 51 patients (17.6%).Family history (p = 0.041), palmoplantar involvement (p = 0.008), PsA (p = 0.097), and bio-experiencedstatus (p = 0.060) were associated with lower odds of being an ESR, whereas each 1-point increase inbaseline PASI was associated with significantly lower odds of ESR (p < 0.001). Gender, age, diseaseduration, history of conventional systemic treatment, and presence of any comorbidity were notsignificantly associated with the likelihood of being an ESR (all p > 0.05).Conclusion: Bimekizumab is the effective treatment in both bio-naïve and bio-experienced patients;however, it may have a more rapid onset of action in bionaive patients. Further studies are needed onthe long-term efficacy and safety data of bimekizumab.